Download PROGRAM Molecular UTI Conference Urinary Tract Infection

PROGRAM
Molecular UTI Conference Urinary Tract Infection; molecular advances and novel therapies Malmö, August 25-­‐‑27th, 2014 Conference venue: The Jubilee auditorium Jan Waldenströms gata 1-­‐‑5, Malmö MONDAY August 25th
08.50
Opening remarks
09.00
KEY NOTE LECTURE
Bruce Beutler, Regental Professor, Director, Center for Genetics of Host
Defense, University of Texas, Southwestern Medical Center, Dallas, Texas,
USA
Coffee
10.00
SESSION 1: HOST SUSCEPTIBILITY TO INFECTION
Chair: Bruce Beutler
Antimicrobial peptides and proteins in defense of the urinary tract
Michael Zasloff, Medstar Georgetown Transplant Institute, Georgetown
University School of Medicine, Washington DC, USA
Using bacteria to understand human innate immune variation
Sam Miller, Department of Microbiology, University of Washington, Seattle,
Washington, USA
Innate Immunity and Genetic Determinants of UTI susceptibility
Catharina Svanborg, Department of Microbiology, Immunology and
Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Lund,
Sweden
Genetic Variation in Vesicoureteral Reflux and its Sequelae
David Hains, Health Science Center, Department of Pediatrics, Division of
Pediatric Nephrology, University of Tennessee, Memphis, Tennessee, USA
Genetic control of acute cystitis; IL-1β and inflammasome dysregulation
Gustav Rydström, Department of Microbiology, Immunology and Glycobiology
(MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden
13.0014.00
Lunch
14.00
SESSION 2: HOST RESPONSE MODULATION BY BACTERIA
INFECTING THE URINARY TRACT
Chairs: Soman Abraham, Ann Stapleton
Unique immune responses of the bladder that predispose to bacterial persistence
Soman Abraham, Center for Microbial Pathogenesis, Duke University Medical
Center, Durham, North Carolina, USA
Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/
interleukin-1 receptor domain–containing proteins
Thomas Miethke, Institute of Medical Microbiology and Hygiene, Medical
Faculty of Mannheim, University of Heidelberg, Mannheim, Germany
Bacterial control of host gene expression through RNA polymerase II
Ines Ambite, Department of Microbiology, Immunology and Glycobiology
(MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden
16.00
Coffee
The fractalkine receptor and its role in glomerulonephritis and pyelonephritis.
Christian Kurts, Institute of Experimental Immunology, University of Bonn,
Bonn, Germany
Innate Immune Suppression by UPEC
David Hunstad, Department of Pediatrics & Department of Molecular
Microbiology, Washington University School of Medicine, Saint Louis, Missouri,
USA
Macrophage depletion improves adaptive immunity to uropathogen infection
Molly Ingersoll, Institut Pasteur, INSERM U818, Paris, France
TUESDAY August 26th
08.30
SESSION 3: PATHOGENESIS
Chairs: Diana Karpman, John Connolly
Redefining ExPEC Virulence by Measuring Gene Expression during Human
Infection
Harry Mobley, Department of Microbiology & Immunology, University of
Michigan Medical School, Ann Arbor, Michigan, USA
Targeted migration of leukocytes: Role of sentinel and helper cells
Daniel Engel, Institute of Experimental Immunology, University Clinic of Bonn
Survival Strategies of Uropathogenic E. coli
Matthew Mulvey, Department of Pathology, Division of Microbiology and
Immunology, University of Utah School of Medicine, Salt Lake City, Utah, USA
Lifting the Mask: Second Generation Small Molecule Inhibitors of
Uropathogenic E. coli Group 2 Capsule Biogenesis
Patrick C. Seed, Division of Infectious Diseases, Department of Pediatrics &
Department of Molecular Genetics and Microbiology, Duke University Hospital,
Duke University, Durham, North Carolina, USA
11.00
Coffee
Bacterial pain phenotypes in the urinary tract
David Klumpp, Department of Urology, Northwestern University, Feinberg
School of Medicine, Chicago, Illinois, USA
Midstream urine culture in the diagnosis of acute uncomplicated cystitis
Thomas M. Hooton, Department of Medicine, Division of Infectious Diseases,
University of Miami, Miami, Florida, USA
Type 1 pili mediate adhesion-based signaling in uropathogenic E. coli
Eric Klein, Center for computational and integrative biology, Rutgers
University, Camden, New Jersey, USA
13.0014.00
Lunch
14. 00
SESSION 4: ASYMPTOMATIC BACTERIAL CARRIAGE – GENOMES
AND HOSTS
Chairs: David Hains, Gabriela Godaly
The paradigm shift to non-treatment in ABU
Lindsay Nicolle, Health Sciences Centre, University of Manitoba, Winnipeg,
Manitoba, Canada
Deliberate establishment of bacteriuria – the therapeutic and research model
Björn Wullt, Department of Microbiology, Immunology and Glycobiology
(MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden
Virulence gene attenuation and genome evolution in human hosts
Ulrich Dobrindt, Institute of Hygiene, University of Münster, Münster, Germany
16.00
Coffee
Protection by E. coli 83972, the US experience
Barbara Trautner, Department of Medicine, Section of Infectious Diseases,
Baylor College of Medicine, Houston, Texas, USA
ABU protects against symptomatic recurrences, results of an RCT in adult
females
Tommaso Cai, Department of Urology, Santa Chiara Hospital, Trento, Italy
Next generation tools for studying UPEC pathogenesis
Swaine Chen, National University of Singapore and Genome Institute of
Singapore
WEDNESDAY August 27th
08.30
SESSION 5: NOVEL THERAPEUTIC APPROACHES
Chairs: Robert Pickard, Chao Sing Ming
Vaccine Candidates and Targets
Harry Mobley, Department of Microbiology & Immunology, University of
Michigan Medical School, Ann Arbor, Michigan, USA
Antimicrobial peptides; Novel strategies to prevent UTI
Annelie Brauner, Department of Microbiology, Tumor and Cell Biology, Division
of Clinical Microbiology, Karolinska Institutet and Karolinska University
Hospital, Stockholm, Sweden
Lactobacilli and probiotic Approaches to Therapy
Ann Stapleton, Division of Allergy and Infectious Diseases & Clinical Research
Center, Institute of Translational Health Sciences, University of Washington,
Seattle, Washington, USA
10.30.
Coffee
Understanding urinary bladder mucosal immunity during UTI: opportunities for
new therapeutic strategies
Scott Hultgren, Department of Molecular Microbiology, Washington University
School of Medicine, St. Louis, Missouri, USA
Non-antibiotic prophylaxis for urinary tract infections
Susanne Geerlings, Division Infectious Diseases, Department of Internal
Medicine, Academic Medical Center, Amsterdam, The Netherlands
D-Mannose – results of a randomized controlled trial
Silvio Altarac, Department of Surgery and Urology, Zabok General Hospital,
Zabok, Croatia
Biomimickry of UPEC cytoinvasion: a novel concept for improved drug delivery
in UTI
Clara Maria Pichl, University of Vienna, Faculty of Life Sciences, Department of
Pharmaceutical Tachnology and Biopharmaceutics, Wien, Austria
13.0014.00
Lunch
14.00
SESSION 6: ANTIBIOTIC RESISTANCE
Chairs: Kurt Naber, Susanne Geerlings
Molecular characterization of the multidrug resistant E. coli ST131 clone
Mark Schembri, School of Chemistry and Molecular Biosciences, University of
Queensland, St. Lucia, Queensland, Australia
Perspectives on antibiotic resistance in UTI
Javier Garau, Department of Medicine, Hospital Universitari Mutua de Terrassa,
Terrassa, Barcelona, Spain
The role of surveillance in the control of resistance – the GPIU study as a model
Florian Wagenlehner, Department of Urology, Pediatric Urology, and
Andrology, Justus Liebig University, Giessen, Germany
16.00
Coffee
FUTURE PERSPECTIVES
An intergrated prospective study of childhood febrile UTI - future applications
from bench to bedside
Chao Sing Ming, Department of Pediatrics, KK Hospital, Singapore, Singapore
UTI susceptibility markers, proteomics and risk assessment: A prospective study
John Connolly, Singapore Immunology Network (SIgN), Biomedical Sciences
Institutes, Agency for Science, Technology, and Research (A*STAR), Singapore,
Singapore
CONCLUDING REMARKS